Home
>
US Stocks
>
Arcus Biosciences Inc
Arcus Biosciences Inc
RCUS

Arcus Biosciences Inc (RCUS)

$35.0821.47%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
33.87
Today Low/High
33.87 / 35.26
52 Week Low/High
$16.69 / $42.36
Market Cap
$2.03B

Company Details

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.
Organisation
Arcus Biosciences Inc
Employees
236
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Arcus Biosciences Inc (RCUS) share price today?

Can Indians buy Arcus Biosciences Inc (RCUS) shares?

How can I buy Arcus Biosciences Inc (RCUS) shares from India?

Can Fractional shares of Arcus Biosciences Inc (RCUS) be purchased?

What are the documents required to start investing in Arcus Biosciences Inc (RCUS) stocks?

We are a SEBI registered investement advisor